Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Exclusion Criteria

• •Prior treatment with IFN-based therapies and/or anti-viral therapies.
• •Women with ongoing pregnancy or breast feeding and male partners of women who are pregnant.
• •Reduced kidney function.
• •Presence of concomitant liver diseases
• •Signs or symptoms of hepatocellular carcinoma.
• •Thyroid disease currently poorly controlled on prescribed medications.
• •History of hemoglobinopathy.
• •Evidence of severe retinopathy.
• •Other serious medical conditions, including human immunodeficiency virus, cancer (excluding non-melanoma skin cancer), or evidence of drug or alcohol abuse.
• •Subjects with documented or presumed coronary artery disease, pulmonary disease, or cerebrovascular disease
• •Clinically significant acute or chronic illnesses.
• •History of severe psychiatric disease, especially depression, characterized by a suicide attempt, hospitalization for psychiatric disease, or a period of disability as a result of psychiatric disease.